Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Total Non-Current Liabilities (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Total Non-Current Liabilities for 10 consecutive years, with $458.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 62.58% to $458.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $458.0 million, a 62.58% decrease, with the full-year FY2025 number at $458.0 million, down 62.58% from a year prior.
  • Total Non-Current Liabilities was $458.0 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $410.6 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $1.2 billion in Q4 2024 to a low of $196.2 million in Q2 2021.
  • A 5-year average of $714.1 million and a median of $574.7 million in 2021 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: surged 397.33% in 2023, then crashed 70.34% in 2024.
  • Ultragenyx Pharmaceutical's Total Non-Current Liabilities stood at $598.8 million in 2021, then soared by 98.41% to $1.2 billion in 2022, then plummeted by 70.27% to $353.3 million in 2023, then surged by 246.47% to $1.2 billion in 2024, then crashed by 62.58% to $458.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Total Non-Current Liabilities are $458.0 million (Q4 2025), $410.6 million (Q3 2025), and $1.1 billion (Q2 2025).